Literature DB >> 16760830

[Correlation between the presence of type-2 anti-pemphigoid antibodies and dementia in elderly subjects with no clinical signs of pemphigoid].

N Foureur1, S Mignot, P Senet, P Verpillat, C Picard-Dahan, B Crickx, C Labarre, P Nicaise-Roland, V Descamps.   

Abstract

BACKGROUND: Pemphigoid is a form of auto-immune bullous dermatosis characterised by the production of antibodies directed against components of hemidesmosomes in the basal membrane. The physiopathological process responsible for unmasking of these antigens is unknown. Pemphigoid is more common in elderly subjects and is most often seen in debilitated subjects. The prevalence of pemphigoid anti-pemphigoid antibodies (anti-PB) is not known in the elderly population presenting no dermatological signs evocative of the disease. We studied the prevalence of anti-PBAg2 antibodies in elderly subjects with no signs of pemphigoid as well as in the correlation between the presence of these antibodies and diagnosis of dementia. PATIENTS AND METHODS: Elderly subjects (aged over 69 years) with no signs of pemphigoid were recruited consecutively in dermatology and geriatrics departments (138 subjects). Details of concomitant medication were recorded for all subjects and clinical examination was performed with calculation of MMS (Mini Mental Score). The subjects were then divided into two groups based on MMS score. The first group comprised subjects without dementia (MMS > 24) while the second comprised subjects with dementia. Serum anti-PBAg2 antibodies were determined by ELISA and indirect immunofluorescence with confirmation by Western blot. Antinuclear antibodies, used as a control for non-specific immune response, were assayed in all serum samples. The prevalence of these antibodies was compared between the two groups.
RESULTS: The two groups were comparable in terms of age, sex and presence of dermatological diseases (ulcers, bedsores, erysipelas). Each group comprised 69 subjects. The overall presence of anti-PBAg2 antibodies in subjects with no signs are suggestive of pemphigoid was 3.6%. Presence of anti-PBAg2 antibodies was associated with diagnosis of dementia (p=0.04; 0% and 7% in groups 1 and 2, respectively). No correlation was seen between the presence of anti-PBAg2 antibodies and concomitant medication or dermatological disease. The overall prevalence of antinuclear antibodies was 14.5% and the figure was similar between the two groups. DISCUSSION: The presence of anti-PBAg2 could be associated with the diagnosis of dementia in elderly subjects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16760830     DOI: 10.1016/s0151-9638(06)70935-8

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  9 in total

1.  Demographics and Autoantibody Profiles of Pemphigoid Patients with Underlying Neurologic Diseases.

Authors:  Kelly N Messingham; Adam D Miller; Nandakumar S Narayanan; Samuel J Connell; Janet A Fairley
Journal:  J Invest Dermatol       Date:  2019-03-12       Impact factor: 8.551

2.  Diagnosis and clinical severity markers of bullous pemphigoid.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  F1000 Med Rep       Date:  2009-02-24

3.  A population-based study of the association between bullous pemphigoid and neurologic disorders.

Authors:  Katherine E Brick; Chad H Weaver; Rodolfo Savica; Christine M Lohse; Mark R Pittelkow; Bradley F Boeve; Lawrence E Gibson; Michael J Camilleri; Carilyn N Wieland
Journal:  J Am Acad Dermatol       Date:  2014-08-29       Impact factor: 11.527

4.  Psychiatric and neurological disorders are associated with bullous pemphigoid - a nationwide Finnish Care Register study.

Authors:  Anna-Kaisa Försti; Jari Jokelainen; Hanna Ansakorpi; Allan Seppänen; Kari Majamaa; Markku Timonen; Kaisa Tasanen
Journal:  Sci Rep       Date:  2016-11-15       Impact factor: 4.379

5.  Analysis of the autoimmune response against BP180 in patients with Alzheimer's disease.

Authors:  Ya-Nan Wang; Christoph M Hammers; Xuming Mao; Hong-Zhong Jin; Jing Yuan; Li Li
Journal:  Ann Transl Med       Date:  2021-01

6.  Detection of underlying dementia in bullous pemphigoid patients using cognitive evaluation tests: a multicenter case-control study.

Authors:  Wenling Zhao; Yiman Wang; Xuming Mao; Aimee S Payne; Suying Feng; Wei Li; Yanhong Wang; Di Wang; Hongzhong Jin; Jing Yuan; Li Li
Journal:  Ann Transl Med       Date:  2020-11

7.  Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients.

Authors:  Antti Nätynki; Päivi Leisti; Jussi Tuusa; Outi Varpuluoma; Laura Huilaja; Kentaro Izumi; Sanna-Kaisa Herukka; Olavi Ukkola; Juhani Junttila; Nina Kokkonen; Kaisa Tasanen
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

Review 8.  Collagen XVII: a shared antigen in neurodermatological interactions?

Authors:  Allan Seppänen
Journal:  Clin Dev Immunol       Date:  2013-06-26

Review 9.  Bullous Pemphigoid: Trigger and Predisposing Factors.

Authors:  Francesco Moro; Luca Fania; Jo Linda Maria Sinagra; Adele Salemme; Giovanni Di Zenzo
Journal:  Biomolecules       Date:  2020-10-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.